Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267601 | 0.93 | POLB (0.55) | PIK3CDPOLBGPR119 | |
| SCHEMBL23608571 | 0.88 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL17672409 | 0.88 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL30044209 | 0.88 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL28850153 | 0.88 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL14377360 | 0.87 | PIK3CD (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL14334113 | 0.87 | PIK3CD (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL15139181 | 0.85 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGPOLB | |
| SCHEMBL15261373 | 0.85 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGPOLB | |
| SCHEMBL20135004 | 0.83 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | PIK3CD 1147/4885PIK3CA 2000/4885PIK3CB 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.